Geron (STU:GON) Ending Cash Position : €175.61 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Geron Ending Cash Position?

Geron's Ending Cash Position for the quarter that ended in Mar. 2024 was €175.61 Mil.

Geron's quarterly Ending Cash Position increased from Sep. 2023 (€29.28 Mil) to Dec. 2023 (€65.23 Mil) and increased from Dec. 2023 (€65.23 Mil) to Mar. 2024 (€175.61 Mil).

Geron's annual Ending Cash Position increased from Dec. 2021 (€31.18 Mil) to Dec. 2022 (€54.01 Mil) and increased from Dec. 2022 (€54.01 Mil) to Dec. 2023 (€65.23 Mil).

Geron Ending Cash Position Historical Data

The historical data trend for Geron's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron Ending Cash Position Chart

Geron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

12.52

8.46

31.18

54.01

65.23

Geron Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															105.68	53.02	29.28	65.23	175.61

Geron Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Geron's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	52.461	+	12.773
	=	65.23

Geron's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	65.448	+	110.162
	=	175.61

Geron Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Geron's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Geron (STU:GON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (STU:GON) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

GERN:USA

Address

919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404

Website

https://www.geron.com

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.

Geron (STU:GON) Headlines

No Headlines